These emerging therapies , Retatrutide, represent a significant advancement in addressing metabolic dysfunction and potentially associated ailments . These drugs are categorized as GLP-1 pathway stimulators, indicating they to mimic the body's GLP-1 hormone , boosting insulin secretion and loweri